FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know On April 15, 2026, the FDA announced a significant regulatory update: injectable GHK-Cu (copper tripeptide-1) will be removed from the Category 2 bulk substances list by July 2026
Further work, utilizing 13 C-MRS, recorded a rapid increase in 13 C-glutamine enrichment early during ketamine infusion in healthy controls and patients with MDD, indicating an acute surge in prefrontal glutamateglutamine cycling 13
Results: GLP-1RAs attenuate inflammation by suppressing NF-B and p38 MAPK pathways, reduce oxidative stress, enhance insulin sensitivity, and promote mitochondrial and endothelial stability

Aqua (Water), Caprylic/Capric Triglyceride, Dipropylene Glycol, Butylene Glycol, Cetearyl Alcohol, Squalane, Cetearyl Olivate, Sorbitan Olivate, Glyceryl Stearate, PEG100 Stearate, Niacinamide, Simmondsia Chinensis (Jojoba) Seed Oil, Cetearyl Ethylhexanoate, 1,2Hexanediol, Betaine, Macadamia Ternifolia Seed Oil, Glutathione, Dimethicone, Sodium Hyaluronate, Carbomer, Arginine, Panthenol, Allantoin, Tocopheryl Acetate, Disodium EDTA, Adenosine, Dipotassium Glycyrrhizate, Parfum (Fragrance), Oryza Sativa (Rice) Bran Extract, Glycyrrhiza Glabra (Licorice) Root Extract, Milk Protein Extract, Punica Granatum Fruit Extract, Cornus Officinalis Fruit Extract, Centella Asiatica Extract, Rosa Damascena Flower Extract, Pulsatilla Koreana Extract, Hippophae Rhamnoides Fruit Extract, Rosa Canina Fruit Extract, Zanthoxylum Piperitum Fruit Extract, Usnea Barbata (Lichen) Extract, Ethylhexylglycerin, Kojyl Carboxy Dipeptide23

Daily Wellness Support: Enhances general wellness routines, supporting long-term balance and overall health for chiropractic patients
If you have gallstones or a history of gallbladder inflammation (cholecystitis), you should be cautious when using GLP-1 medications